Benign Prostatic Hyperplasia Therapeutics Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Benign Prostatic Hyperplasia Therapeutics Market to 2027 - Global Analysis and Forecasts by Product (Alpha blocker, 5-Alpha reductase inhibitor, Phosphodiesterase-5 inhibitor, Others); By Therapy (Mono drug therapy, Combination drug therapy) and Geography

Report Code: TIPRE00004578 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Benign prostatic hyperplasia (BPH), is also known as benign prostatic hypertrophy, which is non-cancerous condition. It is an overgrowth of prostate tissue which is seen at the surrounding of urethra & the bladder. The over growth of tissue blocks the flow of urine, it is most commonly seen in the males above the age of 60 years. BPH is a progressive disease that can cause severe serious problems including renal insufficiency.

MARKET DYNAMICS
The benign prostatic hyperplasia therapeutics market is expected to grow during the forecast period owing to the key driving factors such as rising male geriatric population, awareness related to urological disorder and prostate cancer and others. In addition, various players in the emerging market have strong pipeline product and high potential which are anticipated to create several growth opportunities for the market during the forecast period.

MARKET SCOPE
The "Global Benign Prostatic Hyperplasia Therapeutics Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of benign prostatic hyperplasia therapeutics with detailed market segmentation by product type, therapy and geography. The global benign prostatic hyperplasia therapeutics Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading the benign prostatic hyperplasia therapeutics Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global benign prostatic hyperplasia therapeutics market is segmented on the basis of product type, and therapy. Based on products, the market is segmented as alpha blocker, 5-alpha reductase inhibitor and phosphodiesterase-5 inhibitor. On the basis of therapy, the global benign prostatic hyperplasia therapeutics Market is segmented into mono drug therapy and combination drug therapy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global benign prostatic hyperplasia therapeutics Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The benign prostatic hyperplasia therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting benign prostatic hyperplasia therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the benign prostatic hyperplasia therapeutics Market in these regions.

MARKET PLAYERS
The reports cover key developments in the benign prostatic hyperplasia therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from benign prostatic hyperplasia therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for benign prostatic hyperplasia therapeutics Market in the global market. Below mentioned is the list of few companies engaged in the benign prostatic hyperplasia therapeutics Market.

The report also includes the profiles of key benign prostatic hyperplasia therapeutics Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Astellas Pharma.
  • Allergan plc.
  • Abbott Laboratories
  • Boehringer Ingelheim Pharma GmbH and Co
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Nymox Pharmaceutical
  • Ipsen S.A
  • Eli Lilly and Company
  • Sanofi.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Benign Prostatic Hyperplasia Therapeutics Market - By Product
1.3.2 Benign Prostatic Hyperplasia Therapeutics Market - By Therapy
1.3.3 Benign Prostatic Hyperplasia Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - BY PRODUCT
7.1. OVERVIEW
7.2. BY PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. ALPHA BLOCKER
7.3.1. Overview
7.3.2. Alpha Blocker Market Forecast and Analysis
7.4. 5-ALPHA REDUCTASE INHIBITOR
7.4.1. Overview
7.4.2. 5-Alpha Reductase Inhibitor Market Forecast and Analysis
7.5. PHOSPHODIESTERASE-5 INHIBITOR
7.5.1. Overview
7.5.2. Phosphodiesterase-5 Inhibitor Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - BY THERAPY
8.1. OVERVIEW
8.2. BY THERAPY MARKET FORECASTS AND ANALYSIS
8.3. MONO DRUG THERAPY
8.3.1. Overview
8.3.2. Mono Drug Therapy Market Forecast and Analysis
8.4. COMBINATION DRUG THERAPY
8.4.1. Overview
8.4.2. Combination Drug Therapy Market Forecast and Analysis
9. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Benign Prostatic Hyperplasia Therapeutics Market Overview
9.1.2 North America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis
9.1.3 North America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Product
9.1.4 North America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Therapy
9.1.5 North America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Benign Prostatic Hyperplasia Therapeutics Market
9.1.5.1.1 United States Benign Prostatic Hyperplasia Therapeutics Market By Product
9.1.5.1.2 United States Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.1.5.2 Canada Benign Prostatic Hyperplasia Therapeutics Market
9.1.5.2.1 Canada Benign Prostatic Hyperplasia Therapeutics Market By Product
9.1.5.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.1.5.3 Mexico Benign Prostatic Hyperplasia Therapeutics Market
9.1.5.3.1 Mexico Benign Prostatic Hyperplasia Therapeutics Market By Product
9.1.5.3.2 Mexico Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2. EUROPE
9.2.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Overview
9.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis
9.2.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Product
9.2.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Therapy
9.2.5 Europe Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2.5.2 France Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.2.1 France Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.2.2 France Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2.5.3 Italy Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.3.1 Italy Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.3.2 Italy Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2.5.4 Spain Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.4.1 Spain Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.4.2 Spain Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2.5.5 United Kingdom Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.5.1 United Kingdom Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.5.2 United Kingdom Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.2.5.6 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
9.2.5.6.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market By Product
9.2.5.6.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Overview
9.3.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Therapy
9.3.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.1.1 Australia Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.1.2 Australia Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3.5.2 China Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.2.1 China Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.2.2 China Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3.5.3 India Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.3.1 India Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.3.2 India Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3.5.4 Japan Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.4.1 Japan Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.4.2 Japan Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3.5.5 South Korea Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.5.1 South Korea Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.5.2 South Korea Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.3.5.6 Rest of Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market
9.3.5.6.1 Rest of Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market By Product
9.3.5.6.2 Rest of Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Overview
9.4.2 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Therapy
9.4.5 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Benign Prostatic Hyperplasia Therapeutics Market
9.4.5.1.1 South Africa Benign Prostatic Hyperplasia Therapeutics Market By Product
9.4.5.1.2 South Africa Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.4.5.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market
9.4.5.2.1 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market By Product
9.4.5.2.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.4.5.3 U.A.E Benign Prostatic Hyperplasia Therapeutics Market
9.4.5.3.1 U.A.E Benign Prostatic Hyperplasia Therapeutics Market By Product
9.4.5.3.2 U.A.E Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.4.5.4 Rest of Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market
9.4.5.4.1 Rest of Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market By Product
9.4.5.4.2 Rest of Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Benign Prostatic Hyperplasia Therapeutics Market Overview
9.5.2 South and Central America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Product
9.5.4 South and Central America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Therapy
9.5.5 South and Central America Benign Prostatic Hyperplasia Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market
9.5.5.1.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market By Product
9.5.5.1.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.5.5.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market
9.5.5.2.1 Argentina Benign Prostatic Hyperplasia Therapeutics Market By Product
9.5.5.2.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market By Therapy
9.5.5.3 Rest of South and Central America Benign Prostatic Hyperplasia Therapeutics Market
9.5.5.3.1 Rest of South and Central America Benign Prostatic Hyperplasia Therapeutics Market By Product
9.5.5.3.2 Rest of South and Central America Benign Prostatic Hyperplasia Therapeutics Market By Therapy
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT LABORATORIES
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN PLC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASTELLAS PHARMA
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BOEHRINGER INGELHEIM PHARMA GMBH AND CO
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ELI LILLY COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. GLAXOSMITHKLINE PLC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SANOFI
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. NYMOX PHARMACEUTICAL
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Astellas Pharma.
2. Allergan plc.
3. Abbott Laboratories
4. Boehringer Ingelheim Pharma GmbH and Co
5. Merck & Co., Inc.
6. GlaxoSmithKline plc
7. Nymox Pharmaceutical
8. Ipsen S. A
9. Eli Lilly and Company
10. Sanofi
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book